Macquarie Group LTD Vigil Neuroscience, Inc. Transaction History
Macquarie Group LTD
- $90.3 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding VIGL
# of Institutions
53Shares Held
27.9MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.84MShares$9.92 Million2.45% of portfolio
-
Northpond Ventures, LLC4.21MShares$7.16 Million51.65% of portfolio
-
Siren, L.L.C. New York, NY1.99MShares$3.38 Million0.34% of portfolio
-
Bvf Inc San Francisco, CA1.81MShares$3.08 Million0.2% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.65MShares$2.8 Million1.03% of portfolio
About Vigil Neuroscience, Inc.
- Ticker VIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,268,600
- Market Cap $48.1M
- Description
- Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...